Phosphatidylserine-Gold Nanoparticles (PS-AuNP) Induce Prostate and Breast Cancer Cell Apoptosis.
Allan RadaicNam E JooSoo-Hwan JeongSeong-Ii YooNicholas KotovYvonne L KapilaPublished in: Pharmaceutics (2021)
Prostate and breast cancer are the current leading causes of new cancer cases in males and females, respectively. Phosphatidylserine (PS) is an essential lipid that mediates macrophage efferocytosis and is dysregulated in tumors. Therefore, developing therapies that selectively restore PS may be a potential therapeutic approach for carcinogenesis. Among the nanomedicine strategies for delivering PS, biocompatible gold nanoparticles (AuNPs) have an extensive track record in biomedical applications. In this study, we synthesized biomimetic phosphatidylserine-caped gold nanoparticles (PS-AuNPs) and tested their anticancer potential in breast and prostate cancer cells in vitro. We found that both cell lines exhibited changes in cell morphology indicative of apoptosis. After evaluating for histone-associated DNA fragments, a hallmark of apoptosis, we found significant increases in DNA fragmentation upon PS-AuNP treatment compared to the control treatment. These findings demonstrate the use of phosphatidylserine coupled with gold nanoparticles as a potential treatment for prostate and breast cancer. To the best of our knowledge, this is the first time that a phosphatidylserine-capped AuNP has been examined for its therapeutic potential in cancer therapy.
Keyphrases
- gold nanoparticles
- prostate cancer
- cancer therapy
- oxidative stress
- healthcare
- cell death
- drug delivery
- stem cells
- reduced graphene oxide
- endoplasmic reticulum stress
- squamous cell carcinoma
- combination therapy
- dna methylation
- benign prostatic hyperplasia
- cell proliferation
- circulating tumor
- cell free
- climate change
- cell cycle arrest
- adipose tissue
- young adults
- human health
- smoking cessation
- papillary thyroid
- tissue engineering